Desai, M;
Franklin, BD;
Holmes, AH;
Trust, S;
Richards, M;
Jacklin, A;
Bamford, KB;
(2006)
A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay.
BMC Infectious Diseases
, 6
(June 2)
, Article 94. 10.1186/1471-2334-6-94.
![[thumbnail of A_NEW_APPROACH_PDF.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
A_NEW_APPROACH_PDF.pdf Download (489kB) |
Abstract
Patients prescribed intravenous (IV) glycopeptides usually remain in hospital until completion of this treatment. Some of these patients could be discharged earlier if a switch to an oral antibiotic was made. This study was designed to identify the percentage of inpatients currently prescribed IV glycopeptides who could be discharged earlier if a switch to an oral agent was used, and to estimate the number of bed days that could be saved. We also aimed to identify the patient group(s) most likely to benefit, and to estimate the number of days of IV therapy that could be prevented in patients who remained in hospital.
| Type: | Article |
|---|---|
| Title: | A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/1471-2334-6-94 |
| Publisher version: | http://dx.doi.org/10.1186/1471-2334-6-94 |
| Language: | English |
| Additional information: | © 2006 Desai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. PMCID: PMC1513579 |
| Keywords: | Administration, Oral, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Female, Gram-Positive Bacterial Infections, Humans, Injections, Intravenous, Length of Stay, Male, Teicoplanin, Vancomycin |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1352284 |
Archive Staff Only
 |
View Item |
